## Drug Summary
Cobimetinib, known by its trade name Cotellic, is an orally active MEK inhibitor primarily used in the treatment of unresectable or metastatic melanoma harboring BRAF V600 mutations, often in combination with the BRAF inhibitor vemurafenib. This combination is utilized to counteract the development of resistance often seen with BRAF inhibitor monotherapy due to the reactivation of the MAPK pathway. Cobimetinib functions by selectively inhibiting MEK1 and MEK2 proteins, crucial components of the RAS/RAF/MEK/ERK signaling pathway, which is commonly activated in various cancers. It has demonstrated effectiveness by inhibiting tumor growth, enhancing apoptosis, and is characterized by a bioavailability of 46%, with peak plasma concentrations reached approximately 2.4 hours after intake. 

## Drug Targets, Enzymes, Transporters, and Carriers
Cobimetinib specifically targets the MAP2K1 (MEK1) enzyme, playing a vital role in the downstream signaling of the RAS/RAF/MEK/ERK pathway involved in cellular proliferation and survival. It is metabolized primarily by the enzymes CYP3A4 and UGT2B7, and also by CYP2D6 and CYP3A5, indicating extensive hepatic metabolism. Key transporters involved with cobimetinib include SLCO1B1, SLCO1B3 for uptake by the liver, and efflux transporters such as ABCG2 and ABCB1 which may affect the drug's disposition and toxicity profile. Cobimetinib also binds to the carrier protein ORM1, which could influence its pharmacokinetics and plasma levels.

## Pharmacogenetics
Pharmacogenetic factors can significantly impact the efficacy and safety of cobimetinib. Mutations in the BRAF gene, specifically V600E or V600K, are central to cobimetinibâ€™s efficacy as these are primary determinants for its use in melanoma therapy. Regarding metabolism, variability in the activity of CYP3A4 and UGT2B7 due to genetic polymorphisms could influence the drug's clearance and, consequently, its side effect profile. Polymorphisms in SLCO1B1 and SLCO1B3 could alter hepatic uptake and hence, the systemic exposure of cobimetinib. Additionally, variations in ABCG2 and ABCB1 could modify drug efflux, affecting both efficacy and toxicity. Such genetic factors must be considered to optimize treatment outcomes and minimize adverse effects, making personalized medicine a valuable approach in the therapeutic use of cobimetinib.